Brava Host-Response Panels

In contrast to many lab tests that take 24-36 hours to grow and identify the infectious agent, the Brava Host-Response Panels measure biomarkers that are present early after acute infection. Brava tests will produce results in 15 minutes and will aid in the diagnosis and staging of patients along the disease continuum and monitor progress or decline to guide treatment decisions.

Sepsis is a dysregulated (out of control) systemic immune reaction to infection and is the most expensive disease treated by hospitals. Whether the infection is caused by bacteria (e.g., staph) or a virus (e.g., SARS CoV-2 that causes COVID-19), a continuum of severity exists from Systemic Inflammatory Response Syndrome (SIRS) to septic shock and Multiple Organ Dysfunction Syndrome (MODS).

Sepsis Disease State Overview

  • Worldwide:  Affects 30 million people, 6 million deaths
  • U.S.: 5.3 million tested, 1.1 million diagnosed, 250,000 die
  • Costs $27 billion in the U.S.
  • Highest hospital mortality
  • Sepsis can progress rapidly and can be fatal if not treated quickly
  • Each hour of delay in giving antibiotics increases risk of death by 7%
  • No good tests are available
Sepsis Venn

Clinical Utility of Brava Host-Response Panels

Intended UseAction
Multiple Biomarkers for Sepsis Assessment
Diagnosis: Differentiate between infectious vs. non-infectious etiology at admissionDetermine the need for treatment with broad spectrum antibiotics vs. other intervention associated with non-infectious etiology
Staging: Determine where the patient is on the disease continuum (bacteremia vs. sepsis) at admissionGuide appropriate aggressiveness of treatment and resource allocation for optimal outcomes at lower cost
Monitoring: Assess response to treatment. Determine if empiric antibiotics can be de-escalated after initiation of treatment.Determine whether empirical antibiotic treatment can be weaned (e.g., remove one of the cocktail or all antibiotics)